Advanced searches left 3/3

Carcinoma neoadjuvant - Europe PMC

Summarized by Plex Scholar
Last Updated: 03 September 2022

* If you want to update the article please login/register

Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma.

The clinical use of paclitaxel in an aplastic thyroid carcinoma has been demonstrated. The current research examined the outcomes in ATC patients treated with paclitaxel in a neoadjuvant setting. The collection of ATC patients treated by paclitaxel in our hospital's neoadjuvant setting were reviewed. Patients with and without resection had average OS of 14. 7 and 4. 2 months, respectively. In ATC patients treated with paclitaxel in a neoadjuvant setting, the responses to paclitaxel, resection, and radiotherapy were independent prognostic factors, according to the PI u22652.

Source link: https://europepmc.org/article/MED/36052510


Quantitative RECIST derived from multiparametric MRI in evaluating response of esophageal squamous cell carcinoma to neoadjuvant therapy.

In ESCCs that depend on multiparametric MRI, the aim is to establish a quantitative Response Evaluation Criteria for evaluating response to neoadjuvant therapy in ESCCs relying on multiparametric MRI. Conclusions The qRECIST with mpMRI can identify treatment-induced changes and can be used to determine early detection of nT in ESCC patients. u2022 In distinguishing responders from non-responders, the rate of collaboration between delta RECIST and pathology was 97. 3% for responders and 98. 2% for non-responders, resulting in a total agreement rate of 97. 8%. The rate of convergence between pCRs and non-pCRs was 77. 8% for pCRs and 95. 5% for non-pCRs, resulting in an overall agreement rate of 91. 2%.

Source link: https://europepmc.org/article/MED/36048205


Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: multicentre East Asian and Dutch database comparison.

Patients with different ethnic and genetic histories may respond differently to anticancer drugs. Compared to patients treated in Northwest Europe, patients with oesophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy in East Asia had an inferior pathological response. Patients with OSCR who underwent nCRT were identified from East Asian and Dutch databases between June 2012 and April 2020. Methods Patients with OSCC who underwent nCRT were found among the CROSS protocol and oesophagectomy between June 2012 and April 2020. In Asian than Dutch results, the rate of ypT1-4 was higher than in Dutch ones. In the Asian case, the ypN1-3 rate was 44. 4 percent and 33. 1 percent in the Dutch data set, with 43 percent being 44. 4 percent in the Asian and 33. 1 percent. In 92. 5 percent of Asian and 95. 5 percent of Dutch patients, clear margins were reached. Conclusion Regional shifts in responses to CROSS nCRT for oesophageal cancer were evident, but the source of which would be investigated would be evaluated.

Source link: https://europepmc.org/article/MED/36036665


Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients.

The potential role of programmed cell death 1 inhibitors in primary surgical care of HNSCC and its effects on surgical outcomes are not clear. As part of a window-of-opportunity multi-institutional clinical trial evaluating neoadjuvant pembrolizumab for locally advanced HNSCC, we wanted to determine the incidence of postoperative adverse events in treatment-naive patients with advanced oral cavity cancer receiving neoadjuvant pembrolizumab. The main findings and indicators Incidence of adverse events following surgical resection of advanced OCSCC within 30 days of surgery and on continuing follow-up. Conclusions and relevance This cohort looked at surgical complications among patients receiving neoadjuvant pessimist pegoyab-treated OCSCC treated with neoadjuvant pegylamine, finding that serious adverse events were similar to those in patients undergoing standard-of-care therapy.

Source link: https://europepmc.org/article/MED/36006622


HER2-positive/ER-low breast carcinoma shows a response to neoadjuvant chemotherapy similar to that of HER2-positive/ER-negative breast carcinoma.

ER low staining HER2 negative tumors with ER low staining are considered biologically and clinically equivalent to ER negative tumors. This research investigates whether ER low expression in HER2-positive BCs has different clinical characteristics than ER-negative HER2-positive tumors. We used a sample of 171 patients with HER2+ BCs to assess risk of residual cancer following neoadjuvant chemotherapy with different ER expression strengths. The risk of residual cancer in patients with ER-negative tumors was similar to that in patients with ER-negative tumors. Patients with ER-high tumors had twice the risk of residual cancer compared to those with ER-negative tumors. ER-low tumors had a similar pathologic reaction to chemotherapy in this cohort of patients with HER2+ BCs, as ER-negative tumors have similar clinical symptoms. This similarity between ER negative and ER low breast cancers like the HER2 enriched phenomenon should be addressed by future research, especially biological explanations.

Source link: https://europepmc.org/article/MED/36029679


Lymphovascular and Perineural Invasion after Neoadjuvant Therapy in Esophageal Squamous Carcinoma.

BACKGROUND Lymphovascular invasion and perineural invasion in patients with esophageal squamous cell carcinoma are unfavorable prognostic factors. After neoadjuvant chemoradiotherapy in these patients, however, the prevalence and prognostic value of lymphovascular invasion and perineural invasion is uncertain. Methods We retrospectively reviewed specimens of 321 patients with pathologically diagnosed esophageal squamous cell carcinoma who underwent neoadjuvant chemoradiotherapy in our center from 2017-2020. In 12. 5% and 17. 8% of resection specimens, respectively, the results showed that lymphovascular invasion and perineural invasion were present. According to subgroup reviews, lymphovascular invasion could identify patients with decreased overall survival or disease-free survival among node-negative patients, indicating the presence of lymphovascular invasion in the precise diagnosis of pN0 patients. After neoadjuvant chemoradiotherapy, Lymphovascular invasion was an independent prognostic predictor in esophageal squamous cell carcinoma patients. Following neoadjuvant chemoradiotherapy, Lymphovascular invasion and perineural invasion should be considered in the histopathology study for esophageal squamous cell carcinoma patients.

Source link: https://europepmc.org/article/MED/36027933


Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients.

The new study, published in Thereby, sought to determine the safety and effectiveness of TACEplus PD-1 inhibitor as a neoadjuvant therapy bridging to surgical resection in intermediate-stage HCC patients. Methods Twenty two-stage HCC patients treated with neoadjuvant TACE plus PD-1 inhibitor bridging to surgery were consecutively registered. After the neoadjuvant therapy, the objective response rate and disease control rate were both 75. 0% and 100 percent, respectively; in the meanwhile, alpha-fetoprotein levels were reduced after the neoadjuvant therapy. Both median disease-free survival nor median overall survival were achieved; in addition, the 1-year cumulative DFS rate was 86. 6%; in comparison, the 1-year and 2-year cumulative OS rates were 100. 0% and 76. 4% respectively; In addition, patients with successful downstaging had a longer DFS than those with missed downstaging; in comparison to patients with impaired downstaging, this trend was also observed in evaluating increasing OS accumulating OS. Conclusion Neoadjuvant TACE plus PD-1 inhibitor's satisfactory downstaging rate, acceptable survival profile, and tolerance among intermediate-stage HCC patients has been highly appreciated.

Source link: https://europepmc.org/article/MED/35996068


Neoadjuvant Immunotherapy in the Treatment of Renal Cell Carcinoma: A Case Series

Renal cell carcinoma is a form of urologic cancer with a poor prognosis, with the overwhelming majority of these being clear cell renal carcinoma. In patients with a large tumor burden at diagnosis, we demonstrate the role and benefit of therapy with neoadjuvant immune checkpoint inhibitors, making them ineligible for surgical care in the following three cases.

Source link: https://europepmc.org/article/MED/PMC9387746


Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.

Context. u2014 Neoadjuvant systemic therapy refers to the use of a systemic agent for malignancy prior to surgical intervention, and has recently emerged as an option for many breast cancer patients undergoing adjuvant systemic therapy. The American Joint Committee on Cancer staging system acknowledges the difficulties involved in staging breast carcinomas following neoadjuvant treatment and provides important research data, but does not yet have detailed advice on estimating residual tumor burdens in the breast and lymph nodes. The Residual Cancer Burden system is the only Web-based system that measures treatment response as a continuous variable in the breast and lymph nodes. paraphrasedoutput:u2014 To provide clarifications and guidance for the analysis and reporting of postneoadjuvant breast specimens, address the latest staging and reporting methods, and make future updates to the American Joint Committee on Cancer's Cancer Control System and the Residual Cancer Burden calculator. u2014 Objective: u2014 Objective: To clarify and clarify postneoadjuvant breast specimens, discuss problems with current staging and reporting methods, make specific recommendations for future updates to the American Joint Committee on Cancer Burden's.

Source link: https://europepmc.org/article/MED/35976643


Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study.

Background Although anti-programmed death receptor-1 antibodies have been tested in the neoadjuvant setting for the treatment of locally advanced head and neck cancer, as well as oral cavity squamous cell carcinoma, the overall response rate is modest. The purpose of the current research was to assess the safety and effectiveness of neoadjuvant nivolumab in combination with stereotactic body radiotherapy for the treatment of locally diagnosed OCSCC. Methods OCSCC patients who underwent surgical resection within six months of receiving nivolumab plus SBRT from December 2018 to February 2021 were analyzed retrospectively. Results All 30 healthy participants in this trial enjoyed the neoadjuvant treatment with no adverse events were reported. Neoadjuvant nivolumab plus SBRT is safe and efficacious, and it could be used as a potential neoadjuvant therapy for patients with locally advanced OCSCC.

Source link: https://europepmc.org/article/MED/35972629

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions